Overview
Goserelin is a synthetic decapeptide analogue of gonadotropin-releasing hormone developed by Imperial Chemical Industries, the predecessor of AstraZeneca, and marketed as Zoladex since the late 1980s. Its structure substitutes a tert-butyl-protected D-serine at position 6 and an aza-glycine amide at the C-terminus, modifications that increase resistance to peptidases and extend receptor activity compared with the native hormone.
Goserelin is approved as a prescription medicine for indications including prostate cancer, certain breast cancers and selected gynaecological conditions. It is notable in formulation science because it was one of the first peptides supplied in a biodegradable polymer matrix designed to release the active compound steadily over weeks. In research, goserelin is used alongside other GnRH agonists to study pituitary desensitisation, to create controlled sex-steroid deprivation in experimental models, and to investigate how oestrogen and androgen signalling shape the growth of hormone-dependent tumours. Its long clinical history also makes it a frequent comparator in studies of newer GnRH antagonists.
Mechanism studied
- Goserelin
- GnRH receptor
- Pituitary desensitisation
- Sex steroids ↓
Goserelin acts as an agonist at the GnRH receptor on anterior pituitary gonadotrophs. Its first effect is to stimulate release of luteinising hormone and follicle-stimulating hormone, which transiently raises circulating sex steroids. Continued, non-pulsatile receptor activation then triggers desensitisation: receptors uncouple from Gq signalling, are internalised, and gonadotropin synthesis falls. Over the following weeks, testosterone in males and oestradiol in premenopausal females decline to castrate or postmenopausal ranges in published studies. This reversible suppression of the hypothalamic-pituitary-gonadal axis is the basis of its use as a research tool in endocrine and oncology models.
Research highlights
- 01Developed by ICI in the 1980s as part of the wave of GnRH superagonists that followed the sequencing of native GnRH.
- 02An early example of a peptide formulated in a biodegradable lactide-glycolide polymer for sustained release.
- 03Large trials in early breast cancer helped establish ovarian function suppression as a field of study.
- 04Investigated for ovarian protection during chemotherapy, a research question that continues to generate debate.
- 05Open questions concern long-term bone, metabolic and cardiovascular consequences of prolonged sex-steroid suppression.
Latest published research
1,446 papers on PubMed →Interstitial lung disease associated with antiandrogen agents: a pharmacovigilance study based on FDA adverse event reporting system
Li G et al. · International urology and nephrology · 2026 Nov · PMID 42154420
Overall survival with adjuvant ribociclib plus nonsteroidal aromatase inhibitor in patients with high-risk HR+/HER2- early breast cancer: Six-year follow-up of the NATALEE trial
Slamon DJ et al. · Annals of oncology : official journal of the European Society for Medical Oncology · 2026 Oct 23 · PMID 42918423
Comparison of cardiovascular events in patients with metastatic hormone sensitive prostate cancer treated with LHRH agonists to LHRH antagonists in the US: A retrospective cohort study
Titus RS et al. · Urologic oncology · 2026 Oct 18 · PMID 42892580
Retrospective cross-sectional study of drug utilisation and expenditure of anticancer drugs at zonal referral hospital central, Tanzania
Zimbwe KB et al. · Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026 Oct · PMID 40566830
Darolutamide Alone and in Combination With Goserelin in Androgen Receptor-Positive Salivary Gland Carcinoma: Results From the Phase II DISCOVARY Trial
Okano S et al. · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026 Sep 20 · PMID 42546251
Extrauterine Adenomyoma of the Lung: A Rare Case Report
Zhou M et al. · International journal of women's health · 2026 · PMID 42719860
Fewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan
Kawahara T et al. · Cancer reports (Hoboken, N.J.) · 2026 Sep · PMID 42728640
Exceptional Response to Short-course 177 Lu-PSMA Radioligand Therapy in a Patient With Metastatic Hormone-sensitive Prostate Cancer
Rezaei Borujerdi N et al. · Clinical nuclear medicine · 2026 Sep 1 · PMID 42007836
Live feed from PubMed (NCBI) for “Goserelin”, updated 2026-10-30. Listing a paper is not an endorsement of its findings.
Registered studies
417 on ClinicalTrials.gov →- Active not recruitingPhase 2
Hormone Therapy and Intensity-Modulated Radiation Therapy in Treating Patients With Metastatic Prostate Cancer
NCT00544830 · City of Hope Medical Center · 2006-08-07
- Not yet recruiting
Tolerability of Dalpiciclib vs. Abemaciclib/Ribociclib in Early HR+/HER2- Breast Cancer
NCT07706933 · Henan Cancer Hospital · 2026-11-01
- Active not recruitingPhase 3
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
NCT05827081 · Novartis Pharmaceuticals · 2024-02-28
- Active not recruitingPhase 3
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
NCT01674140 · SWOG Cancer Research Network · 2013-09-12
- Active not recruitingPhase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
NCT02115282 · National Cancer Institute (NCI) · 2014-03-29
- Active not recruitingPhase 4
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195 · Novartis Pharmaceuticals · 2022-07-07
- Active not recruitingPhase 2Phase 3
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT04787744 · VA Office of Research and Development · 2021-07-01
- RecruitingPhase 3
Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer
NCT07751133 · University College, London · 2026-08-28
From the public ClinicalTrials.gov registry for “Goserelin”, updated 2026-10-30. Shown for research context only; Purity Peptides products are not for human use.
Key references
- [1]Manufacturer's prescribing information — FDA / EMA / ANVISA
- [2]PubMed — reviews on goserelin
- [3]WADA — Prohibited List of Substances and Methods
FAQ
Goserelin replaces the glycine at position 6 with a protected D-serine and ends in an aza-glycine amide. These substitutions stabilise the peptide against enzymatic cleavage and increase its potency at the GnRH receptor compared with the native decapeptide.
Goserelin is a GnRH receptor agonist. It initially stimulates gonadotropin release, then suppresses it through receptor desensitisation. This contrasts with antagonists such as degarelix, which block the receptor directly without an initial hormonal flare.
Goserelin is an approved prescription medicine in the US, EU and many other regions for specific oncology and gynaecology indications. As a research compound it is supplied for laboratory investigation only and not for human use.
FOR RESEARCH USE ONLY.Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.